Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bacteriophage P49
- Development stage
- Preclinical
- Lead developer
- West China Hospital of Sichuan University
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
01
Overview
Bacteriophage P49 is a newly identified, broad-spectrum lytic bacteriophage belonging to the genus *Epseptimavirus* (family *Demerecviridae*). It was isolated from wastewater at West China Hospital, Sichuan University, using phage-resistant mutants of carbapenem-resistant *Klebsiella pneumoniae* (CRKP) as host strains. P49 exhibits a rare cross-genus bactericidal activity, capable of lysing not only phage-resistant CRKP mutants but also *Escherichia coli*, *Salmonella enterica*, *Kluyvera tianfuensis*, and *Enterobacter ludwigii*. It targets and binds to the bacterial outer membrane vitamin B12 transport protein BtuB as its receptor. Due to its stability, rapid adsorption, high burst size, and lack of antimicrobial resistance or virulence genes, bacteriophage P49 is a promising candidate for phage therapy, particularly in combination cocktails to overcome bacterial resistance.
- Other names
- phage P49
02
Targets
Cer (Ceramide)
Beyond the preview
Go deeper on bacteriophage P49.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bacteriophage P49.